ReviewHuman vaccines & immunotherapeutics2018
Respiratory syncytial virus seasonality and its implications on prevention strategies.
Review in Human vaccines & immunotherapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 80 citations in OpenAlex.
- Review
- Clinical presentation and hospitalisation risk of RSV in primary care among children younger than 5 years in Italy in four seasons between 2019 and 2023: a multicentre prospective cohort study.The Lancet regional health. Europe · 2026Article
- Aetiology of acute respiratory infection in Vientiane, Lao PDR, from a case-control study.Scientific reports · 2026Article
- Hidden connection: Impact of the gut microbiota on respiratory diseases in children (Review).Molecular medicine reports · 2026Review
- Article
- Review
- Addressing the Underestimated Burden of RSV in Older Adults in Europe: Epidemiology, Surveillance Gaps, and Public Health Implications.Vaccines · 2025Review
- Optimal Timing of Vaccination: A Narrative Review of Integrating Strategies for COVID-19, Influenza, and Respiratory Syncytial Virus.Infectious diseases and therapy · 2025Review
- Prevention of respiratory syncytial virus disease across the lifespan in Italy.Pneumonia (Nathan Qld.) · 2025Review
- Burden of Acute Respiratory Infections Caused by Influenza Virus, Respiratory Syncytial Virus, and SARS-CoV-2 with Consideration of Older Adults: A Narrative Review.Infectious diseases and therapy · 2025Review
- Review
- Differences Between RSV A and RSV B Subgroups and Implications for Pharmaceutical Preventive Measures.Infectious diseases and therapy · 2024Review
- Variability in the Timing of Respiratory Syncytial Virus Epidemics in Guatemala, 2008-2018.Influenza and other respiratory viruses · 2024Article
- Trends in hospitalizations of children with respiratory syncytial virus aged less than 1 year in Italy, from 2015 to 2019.Italian journal of pediatrics · 2024Article
- Sentinel Enhanced Dengue Surveillance System - Puerto Rico, 2012-2022.Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002) · 2024Article
- RSV Infection in Refugees and Asylum Seekers: A Systematic Review and Meta-Analysis.Epidemiologia (Basel, Switzerland) · 2024Review
- Global Seasonal Activities of Respiratory Syncytial Virus Before the Coronavirus Disease 2019 Pandemic: A Systematic Review.Open forum infectious diseases · 2024Review
- Article
- RSV Disease Burden in Primary Care in Italy: A Multi-Region Pediatric Study, Winter Season 2022-2023.Influenza and other respiratory viruses · 2024Article
- Respiratory syncytial virus-associated hospitalizations among children: an Italian retrospective observational study.Italian journal of pediatrics · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With maternal and infant vaccines against respiratory syncytial virus (RSV) in development, it is timely to consider how the deployment of these vaccines might vary according to local RSV disease seasonality. In temperate regions RSV infection is predictably limited to a period of 3 to 5 months, while in tropical regions disease seasonality is often both more variable and more prolonged. Accordingly, in tropical regions a year-round immunisation schedule for both maternal and infant immunisation might be appropriate. In contrast, in temperate regions the benefit of year-round maternal immunisation would be heavily dependent on the duration of protection this provided, potentially necessitating a strategy directed at children due to be born in the months immediately prior to the RSV season. This review will consider the impact of seasonality on maternal and infant immunisation strategies against RSV, and the potential of an alternative approach of passive immunisation for all infants immediately prior to the RSV season.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.